Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NUVL
NUVL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NUVL News
Zidesamtinib Shows Promising Activity in ROS1-Positive NSCLC Patients
3d ago
PRnewswire
Nuvalent Submits NDA for Neladalkib in Advanced NSCLC
Apr 07 2026
NASDAQ.COM
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
Apr 07 2026
PRnewswire
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
Apr 07 2026
Newsfilter
Latest Wall Street Rating Updates
Mar 30 2026
CNBC
Wells Fargo Begins Coverage of Nuvalent, Inc. with Overweight Rating and $116 Target Price
Mar 30 2026
moomoo
S&P 500 Futures Decline in Pre-Market Trading; Nuvalent and Figure Tech Solutions Take the Lead
Mar 26 2026
Barron's
Nuvalent (NUVL.US) Executive Plans to Sell $5.73 Million in Common Stock via Form 144
Mar 24 2026
moomoo
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
PRnewswire
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
Newsfilter
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
Fool
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
NASDAQ.COM
S&P 500 Futures Decline in Pre-Market Session; MongoDB and Credo Tech Group Underperform
Mar 03 2026
Barron's
Nuvalent Reports Q4 Earnings Miss with EPS of -$1.58
Feb 26 2026
seekingalpha
Nuvalent Advances Drug Launch Preparations for FDA Review
Feb 26 2026
PRnewswire
Commodore Capital Sells Nuvalent Shares in SEC Filing
Feb 23 2026
Fool
Show More News
